Erin Macdonald-Dunlop

Erin Macdonald-Dunlop

Auto-generated profile, based on publicly available information

Erin Macdonald-Dunlop

Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
JZJing Hua Zhao
Jing Hua Zhao
DSDavid Stacey
David Stacey
NENiclas Eriksson
Niclas Eriksson
EMErin Macdonald-Dunlop
Erin Macdonald-Dunlop
ÅHÅsa K. Hedman
Åsa K. Hedman
JPJames E. Peters
James E. Peters
Circulating proteins have important functions in inflammation and a broad range of diseases. To identify genetic influences on inflammation-related proteins, we conducted a genome-wide protein quantitative trait locus (pQTL) study of 91 plasma proteins measured using the Olink Target platform in 14,824 participants. We identified 180 pQTLs (59 cis, 121 trans). Integration of pQTL data with eQTL and disease genome-wide association studies provided insight into pathogenesis, implicating lymphotoxin-α in multiple sclerosis. Using Mendelian randomization (MR) to assess causality in disease etiology, we identified both shared and distinct effects of specific proteins across immune-mediated diseases, including directionally discordant effects of CD40 on risk of rheumatoid arthritis versus multiple sclerosis and inflammatory bowel disease. MR implicated CXCL5 in the etiology of ulcerative colitis (UC) and we show elevated gut CXCL5 transcript expression in patients with UC. These results identify targets of existing drugs and provide a powerful resource to facilitate future drug target prioritization.

16 October 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
LFLasse Folkersen
Lasse Folkersen
SGStefan Gustafsson
Stefan Gustafsson
QWQin Wang
Qin Wang
DHDaniel Hvidberg Hansen
Daniel Hvidberg Hansen
ÅHÅsa K. Hedman
Åsa K. Hedman
AMAnders Mälarstig
Anders Mälarstig

24 January 2022 in Aging
Verified
Journal Article
Open access
PDF file
EMErin Macdonald-Dunlop
Erin Macdonald-Dunlop
NTNele Taba
Nele Taba
LKLucija Klarić
Lucija Klarić
AFAzra Frkatović
Azra Frkatović
RWRosie Walker
Rosie Walker
PJPeter K. Joshi
Peter K. Joshi
Biological age (BA), a measure of functional capacity and prognostic of health outcomes that discriminates between individuals of the same chronological age (chronAge), has been estimated using a variety of biomarkers. Previous comparative studies have mainly used epigenetic models (clocks), we use ~1000 participants to compare fifteen omics ageing clocks, with correlations of 0.21-0.97 with chronAge, even with substantial sub-setting of biomarkers. These clocks track common aspects of ageing with 95% of the variance in chronAge being shared among clocks. The difference between BA and chronAge - omics clock age acceleration (OCAA) - often associates with health measures. One year’s OCAA typically has the same effect on risk factors/10-year disease incidence as 0.09/0.25 years of chronAge. Epigenetic and IgG glycomics clocks appeared to track generalised ageing while others capture specific risks. We conclude BA is measurable and prognostic and that future work should prioritise health outcomes over chronAge.

7 April 2022 in Circulation
Verified
Journal Article
Open access
PDF file
ZYZhijian Yang
Zhijian Yang
EMErin Macdonald-Dunlop
Erin Macdonald-Dunlop
JCJiantao Chen
Jiantao Chen
RZRanran Zhai
Ranran Zhai
TLTing Li
Ting Li
XSXia Shen
Xia Shen
Background: SARS-CoV-2, the causal agent of COVID-19, enters human cells using the ACE2 (angiotensin-converting enzyme 2) protein as a receptor. ACE2 is thus key to the infection and treatment of the coronavirus. ACE2 is highly expressed in the heart and respiratory and gastrointestinal tracts, playing important regulatory roles in the cardiovascular and other biological systems. However, the genetic basis of the ACE2 protein levels is not well understood. Methods: We have conducted the largest genome-wide association meta-analysis of plasma ACE2 levels in >28 000 individuals of the SCALLOP Consortium (Systematic and Combined Analysis of Olink Proteins). We summarize the cross-sectional epidemiological correlates of circulating ACE2. Using the summary statistics–based high-definition likelihood method, we estimate relevant genetic correlations with cardiometabolic phenotypes, COVID-19, and other human complex traits and diseases. We perform causal inference of soluble ACE2 on vascular disease outcomes and COVID-19 severity using mendelian randomization. We also perform in silico functional analysis by integrating with other types of omics data. Results: We identified 10 loci, including 8 novel, capturing 30% of the heritability of the protein. We detected that plasma ACE2 was genetically correlated with vascular diseases, severe COVID-19, and a wide range of human complex diseases and medications. An X-chromosome cis–protein quantitative trait loci–based mendelian randomization analysis suggested a causal effect of elevated ACE2 levels on COVID-19 severity (odds ratio, 1.63 [95% CI, 1.10–2.42]; P =0.01), hospitalization (odds ratio, 1.52 [95% CI, 1.05–2.21]; P =0.03), and infection (odds ratio, 1.60 [95% CI, 1.08–2.37]; P =0.02). Tissue- and cell type–specific transcriptomic and epigenomic analysis revealed that the ACE2 regulatory variants were enriched for DNA methylation sites in blood immune cells. Conclusions: Human plasma ACE2 shares a genetic basis with cardiovascular disease, COVID-19, and other related diseases. The genetic architecture of the ACE2 protein is mapped, providing a useful resource for further biological and clinical studies on this coronavirus receptor.

7 September 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
JZJing Hua Zhao
Jing Hua Zhao
DSDavid Stacey
David Stacey
NENiclas Eriksson
Niclas Eriksson
EMErin Macdonald-Dunlop
Erin Macdonald-Dunlop
ÅHÅsa K. Hedman
Åsa K. Hedman
JPJames E. Peters
James E. Peters

5 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
EMErin Macdonald-Dunlop
Erin Macdonald-Dunlop
LKLucija Klaric
Lucija Klaric
LFLasse Folkersen
Lasse Folkersen
PTPaul Reimund Hugo Jan Timmers
Paul Reimund Hugo Jan Timmers
SGStefan Gustafsson
Stefan Gustafsson
JWJames Wilson
James Wilson
We performed the largest genome-wide meta-analysis (GWAMA) (Max N=26,494) of the levels of 184 cardiovascular-related plasma protein levels to date and reported 592 independent loci (pQTL) associated with the level of at least one protein (1308 significant associations, median 6 per protein). We estimated that only between 8-37% of testable pQTL overlap with established expression quantitative trait loci (eQTL) using multiple methods, while 132 out of 1064 lead variants show evidence for transcription factor binding, and found that 75% of our pQTL are known DNA methylation QTL. We highlight the variation in genetic architecture between proteins and that proteins share genetic architecture with cardiometabolic complex traits. Using cis -instrument Mendelian randomisation (MR), we infer causal relationships for 11 proteins, recapitulating the previously reported relationship between PCSK9 and LDL cholesterol, replicating previous pQTL MR findings and discovering 16 causal relationships between protein levels and disease. Our MR results highlight IL2-RA as a candidate for drug repurposing for Crohn’s Disease as well as 2 novel therapeutic targets: IL-27 (Crohn’s disease) and TNFRSF14 (Inflammatory bowel disease, Multiple sclerosis and Ulcerative colitis). We have demonstrated the discoveries possible using our pQTL and highlight the potential of this work as a resource for genetic epidemiology.